The purpose of this paper was to determine the effects of freeze-thaw cycling, protease inhibitors, and array type on the proteome profile of serum and EDTA-plasma.
Protein profiling as a diagnostic tool in clinical chemistry: a review.
Bons JA, Wodzig WK, van Dieijen-Visser MP
Purpose
Conclusion
For frequently thawed serum, proteome profiles on CM10 and NP20 arrays had 3 and 1 peaks, respectively, that distinguished between normal and sarcoidosis cases. However, these same peaks were not significantly different in specimens that had only undergone one freeze-thaw cycle. Addition of protease inhibitors to serum increased the number of peaks in the m/z range of 2500-150,000 Da on the CM10 and NP20 arrays. EDTA-plasma had fewer peaks in the m/z range of 2500-150,000 Da than serum. The addition of protease inhibitors to EDTA-plasma had no effect on peak number on the CM10 array but decreased the number of peaks identified on the NP20 array.
Studies (2)
Purpose
The purpose of this study was to determine the effects of freeze-thaw cycling and array type on the proteome profile of serum from patients with sarcoidosis and normal controls.
Summary of Findings
For frequently thawed serum, the profiles on CM10 and NP20 arrays had 3 and 1 peaks, respectively, that distinguished between normal and sarcoidosis cases. However, these same peaks were not significantly different in freshly frozen specimens that had undergone only one freeze-thaw cycle..
Biospecimens
FluidSerumFluidBloodPreservation Types
FrozenDiagnoses
NormalOther diagnosesPlatforms
ProteinSELDI-TOF MSPeptideSELDI-TOF MSPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Preaquisition Diagnosis/ patient condition SarcoidosisStorage Freeze/thaw cycling 1 cycle>8 cyclesSELDI-TOF MS Specific Type of array CM10NP20
Purpose
The purpose of this study was to determine the effects of using EDTA-plasma rather than serum, protease inhibitors and array type on the proteome profile from patients with sarcoidosis and normal controls.
Summary of Findings
For both the CM10 and NP20 arrays, there were more peaks that could distinguish sarcoidosis from healthy controls when serum was analyzed rather than plasma. Addition of protease inhibitors to serum increased the number of peaks in the m/z range of 2500-150,000 Da on the CM10 and NP20 arrays. The addition of protease inhibitors to EDTA-plasma had no effect on peak number on the CM10 array but decreased the number of peaks identified on the NP20 array.
Biospecimens
FluidPlasmaFluidSerumFluidBloodPreservation Types
FrozenDiagnoses
NormalOther diagnosesPlatforms
PeptideSELDI-TOF MSProteinSELDI-TOF MSPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Preaquisition Diagnosis/ patient condition SarcoidosisBiospecimen Aliquots and Components Blood and blood products PlasmaSerumAnalyte Extraction and Purification Protease inhibitor Added at specimen collectionNo protease inhibitor addedSELDI-TOF MS Specific Type of array CM10NP20